Publicacións en colaboración con investigadores/as de Mayo Clinic (21)

2023

  1. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90

2022

  1. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293

  2. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 9, pp. 1854-1862

  3. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160

2021

  1. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer

    New England Journal of Medicine, Vol. 385, Núm. 25, pp. 2336-2347

  2. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

    npj Breast Cancer, Vol. 7, Núm. 1

  3. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  4. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  5. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

    Oncologist, Vol. 25, Núm. 9, pp. e1346-e1354

2019

  1. Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (BMC Cancer (2019) 19 (517) DOI: 10.1186/s12885-019-5687-0)

    BMC Cancer

  2. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

  3. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

    BMC Cancer, Vol. 19, Núm. 1

  4. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

    Cancer, Vol. 125, Núm. 22, pp. 3974-3984

2018

  1. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

    npj Breast Cancer, Vol. 4, Núm. 1

2017

  1. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study

    Journal of Clinical Oncology, Vol. 35, Núm. 2, pp. 141-148

2015

  1. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials

    The Lancet, Vol. 386, Núm. 10001, pp. 1341-1352

2014

  1. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis

    Journal of Clinical Oncology, Vol. 32, Núm. 10, pp. 1031-1039

  2. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2012

  1. Ixabepilone-associated peripheral neuropathy: Data from across the phase II and III clinical trials

    Supportive Care in Cancer, Vol. 20, Núm. 11, pp. 2661-2668